Life at the Johns Hopkins School of Medicine
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
One of the hottest topics debated in the 2020 presidential race so far has been immigration reform. There has been widespread outrage centered on the… Read More »Their DNA Will Remember: The Long-Term Effects of Childhood Detention
In an essay I published last year for the Lasker Essay Contest (and republished in our blog), I described optogenetics and chemogenetics, two technologies recently… Read More »A Revelation About DREADDs: A New Neuroscience Technique with Promise for Clinical Psychiatric Treatment
From the flower on your front porch to your cousin’s lower back tattoo, butterflies are one of the most immediately recognizable insects due to their… Read More »The Butterfly Effect: Wing Research Method Shows Promise
The technology behind genome sequencing and the science of genomics has advanced incredibly quickly over the past decade. However, in the process, it has come… Read More »Diving into Epigenetics Aboard NASA’s parabolic arc aircraft